Spectranetics acquires balloon catheter company

Candace Stuart | | Cardiovascular Business | Interventional Cardiology

Spectranetics Corp. and AngioScore penned a $230 million deal to serve the peripheral and coronary markets by making AngioScore a wholly owned subsidiary of Spectranetics.   

Spectranetics reported that it will pay $115 million in cash and $115 million in stock to complete the transaction, which is expected be final by the end of June.

AngioScore, of Freemont, Calif., develops, makes and markets specialty balloon catheters to be used in the treatment of coronary and peripheral artery diseases. Colorado Springs, Colo.-based Spectranetics offers minimally invasive laser technologies for vascular treatments, ablation catheters and cardiac lead management devices.

Candace Stuart, Contributor

Related Content

CMS proposes Medicare coverage for transcatheter tricuspid valve replacement
Hydra TAVR valve gains key approval as global reach continues to grow
SAVR outperforms TAVR in patients with bicuspid aortic valves
Intravascular lithotripsy technology now a top priority for many healthcare companies
SCAI president reviews achievements in interventional cardiology in 2024
Treating AFib patients with TAVR still linked to elevated risks

Around the web

Radiology Business
Key takeaways from RSNA 2024 for AI, CT, MRI and the radiology staffing shortage

Several key trends were evident at the Radiological Society of North America 2024 meeting, including new CT and MR technology and evolving adoption of artificial intelligence.

Health Imaging
Use of AI opportunistic screening in CT for cardiovascular disease

Ron Blankstein, MD, professor of radiology, Harvard Medical School, explains the use of artificial intelligence to detect heart disease in non-cardiac CT exams.

Health Imaging
New imaging protocols proposed to curb rise of cardiovascular infections

Eleven medical societies have signed on to a consensus statement aimed at standardizing imaging for suspected cardiovascular infections.